High-risk, Expression-Based Prognostic Long Noncoding RNA Signature in Neuroblastoma.

ABSTRACT:

Background

Current clinical risk factors stratify patients with neuroblastoma (NB) for appropriate treatments, yet patients with similar clinical behaviors evoke variable responses. MYCN amplification is one of the established drivers of NB and, when combined with high-risk displays, worsens outcomes. Growing high-throughput transcriptomics studies suggest long noncoding RNA (lncRNA) dysregulation in cancers, including NB. However, expression-based lncRNA signatures are altered by MYCN amplification, which is associated with high-risk, and patient prognosis remains limited.

Methods

We investigated RNA-seq-based expression profiles of lncRNAs in MYCN status and risk status in a discovery cohort (n = 493) and validated them in three independent cohorts. In the discovery cohort

SUBMITTER: Sahu D 

PROVIDER: S-EPMC6649748 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature